Autoimmune disease

This is the latest episode of the free DDW narrated podcast, “What’s at the forefront of innovation?” It covers three articles written for the for Volume 23, Issue 2 – Spring 2022 of DDW. They are called “Can animal genomics help find therapies for human disease?”, “Understanding and innovating in immunology”, and “Cell and gene […]

UK company Tay Therapeutics has entered into an exclusive license agreement with US biotech VYNE Therapeutics for its oral bromodomain and extra-terminal domain (BET) inhibitor TAY-B2. Tay Therapeutics out-licensed its topical pan-BET inhibitor to VYNE for £16m in upfront and milestone payments in 2021. The out-licensing of both of Tay Therapeutics’ BET inhibitor projects will […]

A team of researchers at the Keck School of Medicine of University of Southern California (USC) have found a drug with the potential for curbing painful hyperinflammation from osteoarthritis, according to results of an animal study. The findings indicate that a drug compound, R805/CX-011, may modulate an important cell receptor in the body’s immune system, […]

Sonoma Biotherapeutics and Regeneron Pharmaceuticals have announced plans to collaborate on the discovery, development and commercialisation of novel regulatory T cell (Treg) therapies for autoimmune diseases. The collaboration will bring together Regeneron’s VelociSuite technologies for the discovery and characterisation of fully human antibodies and T cell receptors (TCRs) with Sonoma Biotherapeutics’ approach to developing and […]

Immutep, a clinical-stage biotechnology company developing novel LAG-3 immunotherapies for cancer and autoimmune disease, has initiated AIPAC-003 (Active Immunotherapy, Eftilagimod Alpha, and Paclitaxel), an integrated Phase II/III trial to evaluate eftilagimod alpha (efti) in combination with paclitaxel for the treatment of metastatic HER2-neg/low breast cancer (MBC).   Regulatory approval has been received in the US […]

Scientists at the Francis Crick Institute have found that high consumption of a common artificial sweetener, sucralose, lowers activation of T cells in mice. If found to have similar effects in humans, one day it could be used therapeutically to help dampen T cell responses. For example, in patients with autoimmune diseases who suffer from […]

GeNeuro, a biopharmaceutical company developing novel treatments for neurodegenerative and autoimmune diseases such as multiple sclerosis (MS), amyotrophic lateral sclerosis (ALS) and the severe consequences of Covid-19, (PASC, post-Covid or Long Covid), has entered into a credit agreement for a total amount of up to €25 million with the European Investment Bank (EIB), supported by […]

Genoscience Pharma, a clinical-stage biotech company developing lysosomotropic drug candidates for the treatment of cancer, fibrosis and auto-immune diseases through autophagy modulation has launched the ABE-LIVER study, along with trial sponsor Grenoble University Hospital.  The trial   This Phase IIb clinical trial will focus on first-line treatment of HepatoCellular Carcinoma (HCC) patients with Genoscience Pharma’s drug […]

CAR-T therapy can be used to eliminate unwanted cells that cause autoimmunity, according to the results of a new study in mice with an autoimmune disease similar to multiple sclerosis (MS).  CAR-T, which uses genetically altered immune cells to destroy cancer cells, has revolutionised treatment of some blood cancers since it was introduced in 2017.  […]

BioSenic’s arsenic trioxide (ATO) autoimmune disease platform has completed a successful Phase IIb trial in chronic Graft vs Host Disease (cGVHD) and is preparing to move to a Phase III trial.  The BioSenic autoimmune platform was created by Medsenic to target systemic autoimmune diseases using ATO as an active anti-inflammatory and immunomodulatory agent.  The Phase […]